Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC
Phase II Trial of Osimertinib in Combination With Stereotactic Ablative Radiation (SABR) in EGFR Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)
Sponsor: AstraZeneca
Listed as NCT03667820, this PHASE2 trial focuses on Non-small Cell Lung Cancer (NSCLC) and remains ongoing. Sponsored by AstraZeneca, it has been updated 17 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
17 versions recorded-
Dec 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
Jul 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE2
-
Jun 2025 — Jul 2025 [monthly]
Active Not Recruiting PHASE2
-
Jan 2025 — Jun 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE2
▶ Show 12 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
May 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Jun 2023 — May 2024 [monthly]
Active Not Recruiting PHASE2
-
Jun 2022 — Jun 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2021 — Jun 2022 [monthly]
Recruiting PHASE2
-
Apr 2021 — Jun 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE2
-
Jun 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
May 2020 — Jun 2020 [monthly]
Recruiting PHASE2
-
May 2019 — May 2020 [monthly]
Recruiting PHASE2
-
Jan 2019 — May 2019 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Oct 2018 — Jan 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Sep 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- University of Texas Southwestern Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .